Drugs Monitor, Page 26

(25 Aug 2020) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization

August 27, 2020

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study https://www.medrxiv.org/content/10.1101/2020.08.20.20178772v1.full.pdf Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were… Continue reading "(25 Aug 2020) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization"

(24 Aug 2020) Remdesivir-associated with better survival

August 26, 2020

Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU https://doi.org/10.1093/jac/dkaa321 A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59-75.5) years, 92% were men… Continue reading "(24 Aug 2020) Remdesivir-associated with better survival"

(24 Aug 2020) Hydroxychloroquine- No significant benefit observed

August 26, 2020

Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study https://doi.org/10.4269/ajtmh.20-0873 This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the… Continue reading "(24 Aug 2020) Hydroxychloroquine- No significant benefit observed"

(22 Aug 2020) Remdesivir- No statistical significant difference compared to SOC

August 26, 2020

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial https://doi.org/10.1001/jama.2020.16349 Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median… Continue reading "(22 Aug 2020) Remdesivir- No statistical significant difference compared to SOC"

(21 Aug 2020) Tocilizumab- early treatment with TCZ and methylprednisolone beneficial

August 26, 2020

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1371/journal.pone.0237831 Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median… Continue reading "(21 Aug 2020) Tocilizumab- early treatment with TCZ and methylprednisolone beneficial"

(17 Aug 2020) Hydroxychloroquine- proven safe in mild to moderate cases

August 21, 2020

Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia https://doi.org/10.1101/2020.08.16.20175752 A cross-sectional study included 2,733 eligible patients subjected to MOH treatment protocol (hydroxychloroquine and zinc) and revisited the clinics within 3-7 days after treatment initiation. This… Continue reading "(17 Aug 2020) Hydroxychloroquine- proven safe in mild to moderate cases"

(14 Aug 2020) Tocilizumab- found safe in patients with hyperinflammation

August 21, 2020

First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia https://doi.org/10.1101/2020.08.12.20173104 In an observational retrospective cohort study, hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. 29 patients received… Continue reading "(14 Aug 2020) Tocilizumab- found safe in patients with hyperinflammation"

(14 Aug 2020) Hydroxychloroquine and Tocilizumab- HCQ shows no benefit, TCZ reduced mortality

August 21, 2020

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study https://doi.org/10.1371/journal.pone.0237693 In this retrospective observational cohort study (NCT04347993) drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients… Continue reading "(14 Aug 2020) Hydroxychloroquine and Tocilizumab- HCQ shows no benefit, TCZ reduced mortality"

(14 Aug 2020) Hydroxychloroquine and tocilizumab- No significant reduction in in-hospital mortality

August 21, 2020

Efficacy of HCQ and TCZ in patients with COVID-19: A single-center retrospective chart review. https://doi.org/10.2196/21758 A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes during hospitalization. Independent t-test and multivariate… Continue reading "(14 Aug 2020) Hydroxychloroquine and tocilizumab- No significant reduction in in-hospital mortality"

(14 Aug 2020) Tocilizumab- post TCZ complications seen in 61% patients

August 21, 2020

Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19 https://doi.org/10.1002/jmv.26429 Seventy-four patients were included in each group. Seven-teen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred >48 hours after… Continue reading "(14 Aug 2020) Tocilizumab- post TCZ complications seen in 61% patients"